Human Gene Therapy - April 2023 - 323

ADENOVIRUS 5 AS A DELIVERY VECTOR
323
REFERENCES
1. Bulcha JT, Wang Y, Ma H, et al. Viral vector
platforms within the gene therapy landscape. Sig
Transduct Target Ther 2021;6(1):53.
2. Reid T, Warren R, Kirn D. Intravascular adenoviral
agents in cancer patients: Lessons from clinical
trials. Cancer Gene Ther 2002;9(12):979-986.
3. Crystal RG. Adenovirus: The first effective in vivo
gene delivery vector. Hum Gene Ther 2014;25(1):
3-11.
4. Peter M, Ku¨hnel F. Oncolytic adenovirus in cancer
immunotherapy. Cancers (Basel) 2020;12(11):3354.
5. David RM, Doherty AT. Viral vectors: The road to
reducing genotoxicity. Toxicol Sci 2017;155(2):
315-325.
6. Chaurasiya S, Fong Y, Warner SG. Oncolytic virotherapy
for cancer: Clinical experience. Biomedicines
2021;9(4):419.
7. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic
inflammatory response syndrome in an ornithine
transcarbamylase deficient patient
following adenoviral gene transfer. Mol Genet
Metab 2003;80(1-2):148-158.
8. Ricobaraza A, Gonzalez-Aparicio M, MoraJimenez
L, et al. High-capacity adenoviral vectors:
Expanding the scope of gene therapy. Int J Mol
Sci 2020;21(10):3643.
9. Lee CS, Bishop ES, Zhang R, et al. Adenovirusmediated
gene delivery: Potential applications for
gene and cell-based therapies in the new era of
personalized medicine. Genes Dis 2017;4(2):43-63.
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred
reporting items for systematic reviews and metaanalyses:
The PRISMA statement. BMJ 2009;339:
b2535
11. Aguilar LK, Shirley LA, Chung VM, et al. Genemediated
cytotoxic immunotherapy as adjuvant to
surgery or chemoradiation for pancreatic adenocarcinoma.
Cancer Immunol Immunother 2015;
64(6):727-736.
12. Chiocca EA, Abbed KM, Tatter S, et al. A phase I
open-label, dose-escalation, multi-institutional
trial of injection with an E1B-Attenuated adenovirus,
ONYX-015, into the peritumoral region of
recurrent malignant gliomas, in the adjuvant setting.
Mol Ther 2004;10(5):958-966.
13. Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB
study of gene-mediated cytotoxic immunotherapy
adjuvant to up-front surgery and intensive timing
radiation for malignant glioma. J Clin Oncol 2011;
29(27):3611-3619.
14. Chiocca EA, Yu JS, Lukas RV, et al. Regulatable
interleukin-12 gene therapy in patients with recurrent
high-grade glioma: Results of a phase 1
trial. Sci Transl Med 2019;11(505):eaaw5680.
15. Barton KN, Stricker H, Elshaikh MA, et al. Feasibility
of adenovirus-mediated hNIS gene transfer
and 131I radioiodine therapy as a definitive
treatment for localized prostate cancer. Mol Ther
2011;19(7):1353-1359.
16. Barton KN, Siddiqui F, Pompa R, et al. Phase I trial
of oncolytic adenovirus-mediated cytotoxic and
interleukin-12 gene therapy for the treatment of
metastatic pancreatic cancer. Mol Ther Oncolytics
2020;20:94-104.
17. Cristofanilli M, Krishnamurthy S, Guerra L, et al. A
nonreplicating adenoviral vector that contains the
wild-type p53 transgene combined with chemotherapy
for primary breast cancer: Safety, efficacy,
and biologic activity of a novel gene-therapy approach.
Cancer 2006;107(5):935-944.
18. Dreno B, Urosevic-Maiwald M, Kim Y, et al.
TG1042 (Adenovirus-interferon-c) in primary cutaneous
B-cell lymphomas: A phase II clinical trial.
PLoS One 2014;9(2):e83670.
19. Freytag SO, Khil M, Stricker H, et al. Phase I study
of replication-competent adenovirus-mediated
double suicide gene therapy for the treatment of
locally recurrent prostate cancer. Cancer Res
2002;62(17):4968-4976.
20. Freytag SO, Stricker H, Pegg J, et al. Phase I study
of replication-competent adenovirus-mediated
double-suicide gene therapy in combination with
conventional-dose three-dimensional conformal
radiation therapy for the treatment of newly diagnosed,
intermediate- to high-risk prostate cancer.
Cancer Res 2003;63(21):7497-7506.
21. Freytag SO, Movsas B, Aref I, et al. Phase I trial of
replication-competent adenovirus-mediated suicide
gene therapy combined with IMRT for prostate
cancer. Mol Ther 2007;15(5):1016-1023.
22. Freytag SO, Stricker H, Lu M, et al. Prospective
randomized phase 2 trial of intensity modulated
radiation therapy with or without oncolytic
adenovirus-mediated cytotoxic gene therapy in
intermediate-risk prostate cancer. Int J Radiat
Oncol Biol Phys 2014;89(2):268-276.
23. Galanis E, Okuno SH, Nascimento AG, et al. Phase
I-II trial of ONYX-015 in combination with MAP
chemotherapy in patients with advanced sarcomas.
Gene Ther 2005;12(5):437-445.
24. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of
Onyx-015, an E1B attenuated adenovirus, administered
intratumorally to patients with recurrent head
and neck cancer. Clin Cancer Res 2000;6(3):798-
806. Erratum in: Clin Cancer Res 2000;6(5):2120.
25. Hecht JR, Bedford R, Abbruzzese JL, et al. A
phase I/II trial of intratumoral endoscopic ultrasound
injection of ONYX-015 with intravenous
gemcitabine in unresectable pancreatic carcinoma.
Clin Cancer Res 2003;9(2):555-561.
26. Hecht JR, Farrell JJ, Senzer N, et al. EUS or percutaneously
guided intratumoral TNFerade biologic with
5-fluorouracil and radiotherapy for first-line treatment
of locally advanced pancreatic cancer: A phase I/II
study. Gastrointest Endosc 2012;75(2):332-338.
27. Herman JR, Adler HL, Aguilar-Cordova E, et al.
In situ gene therapy for adenocarcinoma of the
prostate: A phase I clinical trial. Hum Gene Ther
1999;10(7):1239-1249.
28. Khorana AA, Rosenblatt JD, Sahasrabudhe DM,
et al. A phase I trial of immunotherapy with intratumoral
adenovirus-interferon-gamma (TG1041)
in patients with malignant melanoma. Cancer
Gene Ther 2003;10(4):251-259
29. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled
trial of intratumoral ONYX-015, a selectivelyreplicating
adenovirus, in combination with cisplatin
and 5-fluorouracil in patients with recurrent
head and neck cancer. Nat Med 2000;6(8):879-885.
30. Kieran MW, Goumnerova L, Manley P, et al. Phase I
study of gene-mediated cytotoxic immunotherapy
with AdV-tk as adjuvant to surgery and radiation for
pediatric malignant glioma and recurrent ependymoma.
Neuro Oncol 2019;21(4):537-546.
31. Kubo H, Gardner TA, Wada Y, et al. Phase I dose
escalation clinical trial of adenovirus vector carrying
osteocalcin promoter-driven herpes simplex
virus thymidine kinase in localized and metastatic
hormone-refractory prostate cancer. Hum Gene
Ther 2003;14(3):227-241.
32. Lamont JP, Nemunaitis J, Kuhn JA, et al. A prospective
phase II trial of ONYX-015 adenovirus
and chemotherapy in recurrent squamous cell
carcinoma of the head and neck (the Baylor experience).
Ann Surg Oncol 2000;7(8):588-592.
33. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial
of adenovirus-mediated p53 gene therapy for recurrent
glioma: Biological and clinical results. J
Clin Oncol 2003;21(13):2508-2518.
34. Lang FF, Conrad C, Gomez-Manzano C, et al.
Phase I study of DNX-2401 (delta-24-RGD) oncolytic
adenovirus: Replication and immunotherapeutic
effects in recurrent malignant glioma. J
Clin Oncol 2018;36(14):1419-1427.
35. Makower D, Rozenblit A, Kaufman H, et al. Phase
II clinical trial of intralesional administration of
the oncolytic adenovirus ONYX-015 in patients
with hepatobiliary tumors with correlative p53
studies. Clin Cancer Res 2003;9(2):693-702.
36. Mulvihill S, Warren R, Venook A, et al. Safety and
feasibility of injection with an E1B-55 kDa genedeleted,
replication-selective adenovirus (ONYX015)
into primary carcinomas of the pancreas: A
phase I trial. Gene Ther 2001;8(4):308-315.
37. Mundt AJ, Vijayakumar S, Nemunaitis J, et al. A
Phase I trial of TNFerade biologic in patients with
soft tissue sarcoma in the extremities. Clin Cancer
Res 2004;10(17):5747-5753.
38. Nemunaitis J, Swisher SG, Timmons T, et al.
Adenovirus-mediated p53 gene transfer in sequence
with cisplatin to tumors of patients with non-smallcell
lung cancer. J Clin Oncol 2000;18(3):609-622.
39. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial
of intratumoral administration of ONYX-015, a
replication-selective adenovirus, in patients with
refractory head and neck cancer. J Clin Oncol
2001;19(2):289-298.
40. Nemunaitis J, Linette G, Ali H, et al. Ad-RTS-hIL12
+ Veledimex Regulation of IL-12 Expression in
Human Gene Therapy - April 2023

Table of Contents for the Digital Edition of Human Gene Therapy - April 2023
